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Edited by Michael R. SussmanAbstract Glucocerebrosidase, the deﬁcient enzyme in Gaucher
disease, catalyzes the cleavage of the b-glycosidic linkage of glu-
cosylceramide. A previous study on the enzyme identiﬁed three
disulﬁde bridges and a single sulfhydryl [Lee, Y., Kinoshita,
H., Radke, G., Weiler, S., Barranger, J.A. and Tomich, J.M.
(1995) Position of the sulfhydryl group and the disulﬁde bonds
of human glucocerebrosidase. J. Protein Chem. 14(3), 127–
137] but recent publication of the X-ray structure identiﬁes only
two disulﬁde bridges with three free sulfhydryls [Dvir, H., Harel,
M., McCarthy, A.A., Toker, L., Silman, I., Futerman, A.H. and
Sussman, J.L. (2003) X-ray structure of human acid-b-glucosi-
dase, the defective enzyme in Gaucher disease. EMBO. 4(7),
704–709]. Using chemical modiﬁcations, acid cleavage and enzy-
matic digestion methods, we report that three free sulfhydryls ex-
ist and that the remaining four cysteines form two disulﬁde bonds
located within the ﬁrst 25 amino-terminal residues, supporting
the X-ray structure.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Gaucher disease is an autosomal recessive inherited disease
characterized by a deﬁciency in glucocerebrosidase (GC) activ-
ity. The disease is classiﬁed into three separate categories: type
1, non-neuronopathic, type 2, acute neuronopathic and type 3,
subacute neuronopathic [3]. In its placental form, GC is a
67 kDa membrane-associated glycoprotein involved in the glu-
cosylceramide degradation pathway [4]. Here, we exclusively
use the recombinant form of GC, modiﬁed in vitro to remove
terminal sialic acid, galactose and N-acetylglucosamine resi-
dues to yield mannose terminal GC whose molecular weight
is 60 kDa. It contains four N-linked glycosylation sites and se-
ven cysteine residues. Since the amino acid sequence was de-
duced from the cDNA, there has been much discussion
concerning the structure of GC. Lee et al., using C-14 iodoace-Abbreviations:GC, glucocerebrosidase; SELDI, surface enhanced laser
desorption/ionization – time of ﬂight mass spectrometry
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contains three disulﬁdes between Cys4-16, Cys23-342 and
Cys126-248 and one free sulfhydryl at Cys18 [1]. Recently, X-
ray crystallography showed that GC contains two disulﬁdes be-
tween Cys4-16 and Cys18-23 and three free sulfhydryls Cys126,
Cys248 and Cys342 [2]. In this report, we use acid cleavage to
isolate an N-terminal fragment and chemical reduction meth-
ods to show that two disulﬁdes exist. Furthermore, we combine
chemical modiﬁcation techniques with surface enhanced laser
desorption/ionization – time of ﬂight mass spectrometry (SEL-
DI-TOF MS), Reverse Phase-HPLC (RP-HPLC) followed
by automated Edman degradation to prove that the remaining
three cysteines within GC are free sulfhydryls.2. Materials and methods
2.1. Materials
Recombinant glucocerebrosidase (Imiglucerase 200 U), outdated for
patient use, was obtained from the NIH Clinical Center pharmacy. H4
and gold ProteinChiparrays were purchased from Ciphergen Biosys-
tems Inc. (Fremont, CA). a-Cyano-4-hydroxy-cinnamic acid (CHCA)
and sinapinic acid (SPA) were obtained from Sigma (St. Louis, MO).
The trypsin was obtained from Promega (Madison, WI) and the
iodoacetamide was obtained from Geno Technology Inc. (St. Louis,
MO). Dithiothreitol (DTT) was purchased from GIBCO (Grand Is-
land, NY). Acrylamide was purchased from Bio-Rad (Hercules, CA)
and dialysis cassettes (Slide-A-LyzersTM) were purchased from Pierce
(Rockford, IL).
2.2. Surface enhanced laser desorption/ionization – time of ﬂight mass
spectroscopy (SELDI)
All mass spectra were recorded in positive-ion mode on the SELDI
mass spectrometer PBS IIc ProteinChip Array reader, a linear laser
desorption/ionization-time-of-ﬂight mass spectrometer with time-lag
focusing [5]. Prior to SELDI analysis, 1 ll of matrix (either saturated
CHCA or SPA) in 50% aqueous acetonitrile containing 0.1% triﬂuoro-
acetic acid (TFA) was added to the ProteinChip array to aid in anal-
ysis. Raw data were analyzed using computer software provided by
the manufacturer and are reported as average masses. All other chem-
icals used were analytical grade and the highest purity available.
2.3. Reverse phase-HPLC (RP-HPLC)
GC, or its peptides, were separated on an C18 column
(2.1 · 250 mm, 300 A˚ pore size, Vydac, Hesperia, CA) employing a
Beckman (Fullerton, CA) system Gold HPLC composed of a Model
168 Diode Array Detector and a Model 126 pump module. A linear
gradient from 5% to 65% B solvent over 60 min with 5 min 5% B initial
condition (were solvent A was 0.12% aqueous TFA and solvent B was
0.1% TFA, 12% isopropanol in acetonitrile) was applied at a ﬂow rateblished by Elsevier B.V. All rights reserved.
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sary, reduced in volume by centrifugal evaporation using a Speed Vac
centrifuge (Savant, Holbrook, NY).
2.4. Automated Edman degradation
Amino acid sequence analysis was performed using an Applied Bio-
systems Inc. (Foster City, CA) Procise protein sequencer run in pulsed
liquid mode according to the manufacturer’s protocol. PTH-amino
acids were identiﬁed on-line from a 5 pM PTH-amino acid standard.
Database searches were done against the Swiss Prot Database.
2.5. LC-MS/MS analysis
The fully automated HPLC-MS system consisted of the Ultimate
Nano-HPLC system (LCPackings/Dionex, Sunnyvale, CA) with Fa-
mos microautosampler, Switchos micro switching module, and Ulti-
mate pump module connected online to a ThermoElectron LTQ
NSI-Ion Trap mass spectrometer (San Jose, CA). The reverse phase
separation was conducted using mobile phase A: 2:97.9:0.1 acetoni-
trile:water:formic acid and mobile phase B: 80:19.9:0.1 acetoni-
trile:water:formic acid. Samples were dissolved in 6.3 lL mobile
phase A, injected using the Famos autosampler and trapped on a Pep-
Map trapping column. Peptides were desalted with mobile phase A,
then eluted and separated on a BioBasic C18 column at approximately
400 nl/min using the following gradient program: 5% B (5 min), a lin-
ear gradient of 5–43% B (50 min), 43–95% B (5 min), 95% B (15 min).
The LTQ was operated in positive ion mode with dynamic exclusion
set to repeat count = 1, repeat duration = 30, exclusion duration = 60,
exclusion mass width low = 0.5 amu, exclusion mass width high = 1.0
amu, expiration count = 2. Spectra were acquired in a data dependent
manner with the top ﬁve most intense ions in the MS scan selected for
MS/MS. A threshold of 3000 was required to trigger MS/MS.2.6. Data searching
RawMS/MSﬁles were submitted to theNIHMascot [6] Cluster using
Mascot Daemon. Data were searched against the SwissProt Trembl
database using a restricted taxonomy of Homo sapiens (human), enzy-
matic cleavage = trypsin, variable modiﬁcations = carboxamidomethyl
(C) and oxidation (M) OR, variable modiﬁcations = propionamide
(C), and oxidation (M),monoisotopicmass, peptide tolerance = 1.5 Da,
MS/MS tolerance = 0.8 Da, one missed cleavage, charge state = 1+, 2+,
and 3+, instrument = ESI-TRAP.
2.7. N-terminal peptide isolation and disulﬁde bond reduction
Recombinant GC, 200lg in 100 ll of water, was added to 100 ll of
glacial acetic acid to achieve a 50% solution by volume (1 lg/ll concen-
tration) [7]. The solution was left overnight at 55 C and analyzed
using SELDI (with SPA as matrix) to monitor progress of the cleavage
at aspartic acid-proline sites. One hundred ll of this solution was chro-
matographed on RP-HPLC and all fractions were collected manually,Fig. 1. The complete amino acid sequence of glucocerebrosidase showing the
cysteines are in bold and circled.spotted on gold ProteinChip arrays (CHCA matrix) and analyzed.
Peaks whose molecular weight corresponded to the N and C-terminals
were also sequenced by Edman degradation to conﬁrm their identity.
The N-terminal fragment was taken to dryness in a speed vac. Tri-n-
butylphosphine (TBP), 10 ll from a stock solution containing 30 ll
of TBP in 970 ll of isopropanol, was added to the dried fragments.
Immediately after addition of TBP, 10 ll of acrylamide (35 mg/ml in
4% aqueous triethylamine) was applied [8]. The mixture was vortexed
and left at room temperature for 15 min. A small amount (1 ll) was
then applied to an H4 ProteinChip for analysis.
2.8. Chemical modiﬁcation of free sulfhydryls
In order to modify free sulfhydryls, GC (80 lg) was recovered from
a clinical preparation by RP-HPLC and reduced to near dryness with a
speed vac. Any free sulfhydryls were alkylated with 5 mM iodoaceta-
mide in 100 ll of 100 mM Tris, pH 7.4. The mixture was left at room
temperature for 30 min. After alkylation, 100 ll of 100 mM Tris, pH 8
was added along with 0.5 lg of trypsin and the digestion was left over-
night in 37 C. Separation of the peptides was performed using RP-
HPLC and all signiﬁcant peaks were manually collected. Aliquots from
the digest and the collected peaks were spotted on ProteinChips (H4
for digests, gold for peaks) for SELDI analysis. Based on their mass
spectral proﬁle, speciﬁc peaks were subjected to automated Edman
degradation to determine their amino acid sequence.
2.9. Reduction and alkylation with acrylamide
To examine the possibility that disulﬁde linkages exist beyond the N-
terminal, 160 lg of GC from a clinical preparation was fractionated by
RP-HPLC. The manually collected fraction was then reduced to near
dryness in a speed vac and enough 50 mM Tris, pH 8 was added to
bring the total volume to 100 ll. Iodoacetamide (5 mM) was then
added and left in the dark for 45 min. The reaction mixture was then
dialyzed against water (4 changes over 24 h) and reduced to almost
dryness in a speed vac. The treated GC was reduced with 45 mM
DTT (in 70 ll of 100 mM Tris, pH 8) at 55 C for 45 min. Alkylation
was then performed with acrylamide (3 ll from a stock solution of
7 mg in 100 ll of 100 mM Tris, pH 8). After 30 min at room tempera-
ture, 200 ll of 100 mM Tris, pH 8 was added along with 0.5 lg of tryp-
sin and left overnight at 37 C.3. Results
3.1. Identiﬁcation of N-terminal disulﬁde bonds
We utilized protein chemistry techniques to examine the
conﬂict regarding the number and position of disulﬁdes and
free sulfhydryls in GC. This controversy arose following pub-
lication of the X-ray crystal structure of GC in which the num-three acetic acid cleavage sites (w) and four glycosylation sites (r). All
Fig. 2. SELDI spectra of recombinant glucocerebrosidase (A). Acetic acid cleavage of GC (B) shows the C-terminal fragment at m/z 2670.4 and the
N-terminal fragment at m/z 3816.4 (expected m/z 2927.3 plus carbohydrate). The isolated N-terminal fragment after RP-HPLC, (C) and the same
fragment after reduction with TBP and alkylation with acrylamide (D) are shown. The mass diﬀerence between panels (C) and (D) corresponds to the
addition of four acrylamide groups to the four cysteines within the N-terminal fragment. All values are expressed as mass/charge ratios (m/z). The
unlabeled peak in panel (A) corresponds to the double charged peak from GC.
Fig. 3. SELDI spectra of the three free sulfhydryl containing peptides and their respective sequence. The other peptide in panel (B) co-eluted with our
peptide of interest and its molecular weight and sequence corresponds to an expected GC tryptic fragment.
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ported at odds with previous chemically derived data. Treat-
ment with 50% acetic acid should cleave at Asp-Pro
sequences located at Asp27-Pro28, Asp298-Pro299 and
Asp474-Pro475 thereby providing a limited number of frag-
ments (Fig. 1). The low pH reduces the probability of base-catalyzed disulﬁde interchange in the case of the unmodiﬁed
GC.
Following this treatment, several fragments from the chemi-
cally cleaved GC were generated. SELDI spectra of the RP-
HPLC fractions (CHCA as matrix) clearly revealed both the
N- and C-terminal peptides (Fig. 2) and their identity conﬁrmed
Table 1
Masses of the three free sulfhydryl containing peptides
Sequence Residues Calculated
mass
Observed
mass
LQFWAVTAENEPS-
AGLLSGYPFQCLG-
FTPEHQR
225–257 3750.8 3749.4
LFPNTMLF-
ASEACVGSK
330–346 1871.9 1871.1
VPMASCDFSIR 121–131 1282.5 1297.1a
aA diﬀerence of 16 is due to the oxidation of a methionine.
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tion, alkylation and SELDI analysis (as described in Section
2), showed an increase in molecular weight consistent with an
addition of four acrylamide groups (from m/z of 3819 to m/z
4106). This demonstrates that all four cysteine residues within
theN-terminal fragment form two intra-peptide disulﬁde bonds.
3.2. Determination of free sulfhydryls in GC
To distinguish possible free sulfhydryls from cysteines in-
volved in disulﬁdes within GC, we modiﬁed the protein with
iodoacetamide without prior reduction. Following this treat-
ment, we cleaved the protein with trypsin and used RP-HPLC
to separate the resulting peptides. Upon manual collection of
the RP-HPLC peaks, we identiﬁed carboxamidomethyl pep-
tides based on their molecular weight (SELDI, Fig. 3) and
their amino acid sequence (Edman, Table 1). As the X-ray
structure shows, we provide evidence that Cys126, 248 and
342 are free sulfhydryls.
3.3. Reduction and alkylation with acrylamide
To investigate the possibility that a subpopulation of the pro-
posed free sulfhydryls exist in any disulﬁde linkages, we reduced
carboxamidomethylated GC with DTT and alkylated with
acrylamide to label any cysteines which may be in a disulﬁde
linkage or not labeled completely by iodoacetamide. This mix-
ture was then digested with trypsin and submitted to LC-MS/
MS for analysis. In addition to identifying the above noted car-
boxamidomethylated peptides, a single low abundance peptide
containing Cys 126 was found with an acrylamide modiﬁcation.4. Discussion
In this report, we investigated the apparent conﬂict in the lit-
erature concerning the number of disulﬁdes and free sulfhydr-
yls in glucocerebrosidase. To address this, we performed two
separate experiments with two diﬀerent goals. First, we use
chemical cleavage and modiﬁcation methods to show that
the four N-terminal cysteines are involved in two disulﬁde link-
ages. Second, we used common alkylation protocols coupled
with mass spectrometry and Edman degradation to prove that
the remaining three cysteines are free sulfhydryls.
We cleaved recombinant GC with 50% acetic acid and ran
the resulting solution on RP-HPLC. The isolated N-terminal
fragment was subjected to reduction (with TBP) and alkylation
(with acrylamide) and subsequent SELDI analysis to conﬁrm
the addition of four acrylamide moieties to Cys residues 4,
16, 18 and 23.The proposed free sulfhydryls were labeled with iodoaceta-
mide without any prior reduction and digested with trypsin
followed by RP-HPLC. All manually collected peaks were
analyzed with SELDI and those peaks whose molecular weight
matched the peptides of interest were sequenced with auto-
mated Edman degradation. We also performed a reduction
(with DTT) and an alkylation (with acrylamide) on an aliquot
of iodoacetamide treated GC. Tryptic digestion of this sample
when analyzed by LC-MS/MS conﬁrmed the presence of car-
boxamidomethyl free sulfhydryls at positions 126, 248 and
342. This analysis also uncovered a minor amount of the Cys
126 peptide labeled with acrylamide. Since neither of the other
free sulfhydryls were found with acrylamide, we believe this to
be a result of incomplete alkylation with iodoacetamide.
In our previous attempts to correctly identify the free sul-
fhydryls in GC, we used 4-vinylpyridine to modify the cysteines.
We then digested the enzyme and examined the resulting pep-
tides with LC-MS/MS; this method identiﬁed three pyridylethyl
cysteines. Reduction and a second alkylation of pyridylethyl-
glucocerebrosidase followed by trypsin digestion was per-
formed. Analysis of this digest by LC-MS/MS proved ambigu-
ous with double labeling of the previously identiﬁed cysteines.
Our results, which show the presence of two disulﬁde link-
ages within the ﬁrst 25 amino acids and the remaining three
cysteines being free, support the X-ray crystal structure [2].
Previous accounts, including the ﬁrst to report disulﬁde bonds
in GC [9], were inaccurate in identifying the number of disul-
ﬁdes [1]. This discrepancy may be due to excessive disulﬁde
interchange that occurred in their experiments.
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